LY-334370 explained

LY-334370 is a selective 5-HT1F receptor agonist[1] which was under development by Eli Lilly and Company for the treatment of migraine headaches.[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.[4]

See also

Notes and References

  1. Dupuis DS, Colpaert FC, Pauwels PJ . G-protein activation at 5-HT1A receptors by the 5-HT1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines . Br. J. Pharmacol. . 124 . 2 . 283–90 . 1998 . 9641544 . 10.1038/sj.bjp.0701832 . 1565387.
  2. Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, Boyce S, Hill R, Hargreaves R . Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY-334,370 . Cephalalgia . 19 . 10 . 851–8 . 1999 . 10668103 . 10.1046/j.1468-2982.1999.1910851.x . 8439008 .
  3. Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, Schaus JM, Ferrari MD . Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial . Lancet . 358 . 9289 . 1230–4 . 2001 . 11675061 . 10.1016/S0140-6736(01)06347-4 . 39926402 .
  4. Ramadan NM, Buchanan TM . New and future migraine therapy . Pharmacol. Ther. . 112 . 1 . 199–212 . 2006 . 16797716 . 10.1016/j.pharmthera.2005.04.010 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "LY-334370".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.